3350 Riverwood Parkway SE
Suite 1900
Atlanta, GA 30339
United States
678 392 3419
https://www.inhibikase.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 8
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Milton H. Werner Ph.D. | CEO, President & Director | 697.96k | N/A | 1964 |
Mr. Garth Lees-Rolfe CPA | Chief Financial Officer | N/A | N/A | 1985 |
Dr. Roger Rush | Head of Preclinical Research | N/A | N/A | N/A |
Dr. Surendra Singh | Head of Chemistry, Manufacturing & Controls | N/A | N/A | N/A |
Dr. Charles Warren Olanow B.Sc., F.R.C.P.C., M.D. | CEO of Clintrex Research Corporation & Member of Scientific Advisory Board | N/A | N/A | N/A |
Dan Williams | Controller | N/A | N/A | N/A |
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
Inhibikase Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.